{"url_path":"/sec/elvn/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1672619/0001193125-26-266731-index.html","accession_number":"0001193125-26-266731","cik":"0001672619","ticker":"ELVN","issuer_name":"Enliven Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1672619/0001193125-26-266731-index.html","primary_entity_key":"0001672619","primary_entity_name":"Enliven Therapeutics, Inc."},"word_count":138,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) issued a press release announcing updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (“CML”). The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nAll of the information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}